August 5, 2015By Mark Terry, BioSpace.com Breaking News Staff After Dublin-based Shire (SHPG) publicly announced its intentions of buying Illinois-based Baxalta (BXLT) yesterday in an attempt to convince shareholders to pressure management into considering the deal, analysts are speculating on what a merged Shire and Baxalta would look like. On July 10, 2015, Shire approached […]

AstraZeneca (AZN.L), under pressure from falling sales of older drugs, is selling a medicine for a rare type of cancer to Sanofi (SASY.PA) as it continues a drive to raise cash by divesting certain assets. Sanofi’s rare diseases division Genzyme will pay AstraZeneca up to $300 million for global rights to Caprelsa, including an upfront […]

BOULDER, Colo., July 22, 2015 /PRNewswire/ — AstraZeneca today announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. This combination therapy showed an adverse event profile generally consistent with current knowledge of the […]

Biogen said on Thursday it had forged a deal with AGTC to develop gene-based therapies for a range of eye diseases, marking the company’s entry into opthalmology. Shares of AGTC, formally known as Applied Genetic Technologies Corp, surged 21 percent to $19.75 in morning trading on the Nasdaq after the announcement. Biogen shares were little […]

July 2, 2015By Alex Keown, BioSpace.com Breaking News Staff CAMBRIDGE, Mass. — Biogen, Inc. and AGTC (AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, entered into an agreement worth more than $1 billion to develop gene-based therapies for multiple ophthalmic diseases, the Two companies […]

A skin-darkening drug can help protect against serious pain in people with a rare inherited condition that makes them flee sunlight like movie vampires, according to tests in Europe and the U.S. The condition, known as erythropoietic protoporphyria, causes severe burning skin pain after several minutes of direct sun exposure. The pain can last for […]

BioMarin Pharmaceutical Inc said its experimental drug was effective in improving growth in children with the most common form of dwarfism in a mid-stage study. The company’s shares rose 6.5 percent to $131 in after-hours trading on Wednesday. The drug, BMN 111 (vosoritide), was evaluated in children with achondroplasia, the most common form of dwarfism, […]